PolyNovo Limited (ASX:PNV)

Australia flag Australia · Delayed Price · Currency is AUD
1.375
-0.085 (-5.82%)
Sep 26, 2025, 4:13 PM AEST
-46.29%
Market Cap 949.91M
Revenue (ttm) 128.70M
Net Income (ttm) 13.21M
Shares Out 690.84M
EPS (ttm) 0.02
PE Ratio 72.76
Forward PE 61.49
Dividend n/a
Ex-Dividend Date n/a
Volume 3,628,460
Average Volume 4,665,826
Open 1.440
Previous Close 1.460
Day's Range 1.357 - 1.440
52-Week Range 0.930 - 2.680
Beta 1.56
RSI 46.75
Earnings Date Nov 24, 2025

About PolyNovo

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to tre... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1998
Employees 301
Stock Exchange Australian Securities Exchange
Ticker Symbol PNV
Full Company Profile

Financial Performance

In 2025, PolyNovo's revenue was 128.70 million, an increase of 24.67% compared to the previous year's 103.23 million. Earnings were 13.21 million, an increase of 151.17%.

Financial Statements

News

ASX falls, weighed down by health sector; gold stocks surge

Shares open lower; Santos signs up Orica for Narrabri gas; Boss sets December deadline for Honeymoon mine review; PolyNovo chairman buys $52k worth of shares. Follow live.

17 days ago - The Australian Financial Review

ASX 200 LIVE: ASX to fall; Collins Foods reaffirms guidance, gold nears $US3500

Bourse weighed down as large caps trade ex-dividend; Collins Foods boosted by sales jump; Platinum dumped after client pulls funds; PolyNovo says it’s placed to benefit from US changes. Follow live.

26 days ago - The Australian Financial Review

PolyNovo chief executive steps down after dispute with chairman

The burns treatment biotech has had a difficult year and now Swami Raote is leaving after a slump in the company’s share price and a brawl with the board.

7 months ago - The Australian Financial Review

David Williams says he makes no apologies for ‘aggressive’ style

The outspoken investment banker is the chairman of PolyNovo. The burns treatment company’s chief executive is leaving after a falling out with the board.

7 months ago - The Australian Financial Review

Polynovo Ltd (CALZF) (Q4 2024) Earnings Call Transcript Highlights: Record Revenue and ...

Polynovo Ltd (CALZF) (Q4 2024) Earnings Call Transcript Highlights: Record Revenue and Strategic Growth

1 year ago - GuruFocus